Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received ...
Profluent and Lilly teamed up on AI‑designed enzymes in a deal worth up to $2.25B. Big tech, bigger gene edits.
VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announced, further to its news release ...
A Canadian-led research team has developed a promising new malaria vaccine, now in preclinical testing with international ...
The biotech will look for tumor-specific antigens in Gustave Roussy patients, which will inform preclinical studies a colorectal and pancreatic cancer therapy.
Morning Overview on MSN
J&J says AI is cutting drug-discovery lead times roughly in half
At a Reuters conference earlier this year, Johnson & Johnson chief information officer Jim Swanson offered a striking number: ...
Under the agreement, Attentive Science will distribute Innovive’s full portfolio of wash-free recyclable caging systems, racks, and consumables, while also collaborating on the regional expansion of ...
A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing ...
Island Pharmaceuticals’ March quarterly update highlights considerable progress advancing the clinical development pathway ...
In vitro data demonstratedself-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 ...
AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one ...
Fungal infections caused by Candida species pose a growing threat to global health, particularly in immunocompromised and critically ill patients. The rise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results